0
0
A recent international study has revealed that India’s growth in cancer-related clinical research has been largely inconsistent since 2001, even as the country experienced strong economic development. This uneven progress reflects broader disparities seen across low- and middle-income countries (LMICs), where cancer clinical trials remain disproportionately concentrated in wealthier nations. The findings highlight the need for more coordinated support to strengthen cancer research capabilities in India and similar contexts.
Key Findings on Cancer Research in India and LMICs
The study, published in the peer-reviewed journal CANCER, analyzed data from the World Bank and ClinicalTrials.gov covering clinical trials registered between 2001 and 2020. Globally, 16,977 cancer clinical trials were registered in LMICs during this period, with trials rising from 1,053 in 2001-2005 to 7,661 in 2016-2020. In India specifically, 54 trials were registered between 2001 and 2005, increasing to 126 trials during 2016-2020, with a total of 506 trials documented through 2020.
Despite India’s robust economic growth over two decades, the progression in cancer research has been irregular, contrasting with steady advances in countries such as China and South Korea. Other South and Southeast Asian nations like Thailand and Vietnam—also experiencing economic growth—showed similar inconsistent trial activity. Interestingly, some South American countries with relatively stagnant economies, such as Argentina, Brazil, and Mexico, recorded meaningful increases in cancer clinical trials.
Expert Perspectives
Max S. Mano, senior author of the study and a researcher at the Latin American Cooperative Oncology Group and Einstein Hospital Israelita in Brazil, emphasized that while economic development influences research capacity, it is not the sole driver. He noted, “These data reinforce the need for initiatives to support cancer research in LMICs.” The authors call for more systematic efforts to build independent and high-complexity clinical research programs in India to match its growing cancer burden.
Context and Background on Cancer Burden in India
India faces a rising cancer burden with cases projected to increase from an estimated 1.46 million in 2022 to 1.57 million by 2025. Lung cancer remains the leading cancer among males and breast cancer among females. Population aging, enhanced detection methods, and changing risk factors contribute to this upward trend, reinforcing the urgency for robust clinical research to develop tailored prevention and treatment strategies.
Implications for Public Health
The uneven growth in clinical research trials can impact the development of effective cancer therapies and prevention measures tailored to the Indian population. Clinical trials are crucial for generating evidence on local genetic, environmental, and lifestyle factors. Improving India’s research infrastructure could reduce disparities in cancer outcomes and align medical advances more closely with population needs, ultimately benefiting patients and healthcare providers.
Potential Limitations and Conflicting Views
The study acknowledges that economic growth alone cannot explain disparities in trial registrations. Factors such as healthcare infrastructure, regulatory environments, funding availability, and prioritization of research also play critical roles. Additionally, data gaps exist, including limited population-based cancer registries covering all Indian states, which may affect the representativeness of research activity and cancer burden estimates.
Practical Implications for Readers
For healthcare professionals and the general public, these findings underscore the importance of advocating for enhanced cancer research support in India. Patients should be aware that clinical research participation opportunities may be limited compared to high-income countries, though ongoing efforts aim to expand trials. Supporting policies that increase funding and streamline approvals can help accelerate the development of cancer treatments adapted to Indian needs.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Economic Times Health. “Study finds disparities in cancer research in India since 2001 despite economic growth.” October 20, 2025.
